Premium
Disposition of drugs in cystic fibrosis. III. Acetaminophen
Author(s) -
Hutabarat Renta M,
Unadkat Jashvant D,
Kushmerick Patricia,
Aitken Moira L,
Slattery John T,
Smith Arnold L
Publication year - 1991
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1991.209
Subject(s) - acetaminophen , cystic fibrosis , medicine , pharmacokinetics , clinical pharmacology , pharmacology
The disposition of acetaminophen after oral administration was investigated in adults with cystic fibrosis (n = 5) and in age‐matched healthy control subjects (n = 5). The total plasma clearance of acetaminophen was found to be greater (p < 0.025) in subjects with cystic fibrosis (0.362 ± 0.081 L/hr/kg) than in control subjects (0.247 ± 0.022 L/hr/kg). This difference in clearance was found to be primarily attributable to a greater metabolic clearance of acetaminophen to acetaminophen sulfate (0.080 ± 0.023 L/hr/kg for subjects with cystic fibrosis and 0.045 ± 0.008 L/hr/kg for control subjects; p < 0.05) and to a greater metabolic clearance of acetaminophen to acetaminophen glucuronide (0.189 ± 0.051 L/hr/kg for subjects with cystic fibrosis and 0.114 ± 0.017 L/hr/kg for control subjects; p < 0.05) in persons with cystic fibrosis. Of the mechanisms that may be responsible for these differences, the most likely is enhanced activity (in subjects with cystic fibrosis) of the transferases that mediate the metabolism of acetaminophen to acetaminophen sulfate and acetaminophen glucuronide, respectively. Clinical Pharmacology and Therapeutics (1991) 50 , 695–701; doi: 10.1038/clpt.1991.209